If increasing dose, would you expect a higher risk of malignancy with IL-23 inhibition?
The faculty continue the discussion on up-titration and more specifically if this causes an increased risk of malignancy with IL-23 inhibition.
The Psoriasis Management, Psoriasis Treatment and Psoriasis Guidelines content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The Expert Opinion and PsoMOT content has been developed by EPG Health for Medthority in collaboration with the sponsor Almirall S.A., utilising content from their Almirall funded symposium at EADV 2021 and PsoMOT meeting in November 2019.